Structure Therapeutics Inc. reported its first-quarter 2026 financial results and shared new efficacy data for its oral weight-loss drug candidate [1].
The results are significant as the company seeks to develop an oral alternative to injectable GLP-1 receptor agonists, which currently dominate the obesity treatment market. A successful oral candidate could increase patient adherence and expand the accessibility of these therapies [1], [2].
In the disclosed data from the Phase 2 ACCESS II trial, the oral candidate aleniglipron demonstrated a maximum body-weight loss of 16.3% [2]. This measurement was recorded at the 44-week mark of the study [2].
These figures represent an increase over earlier data reported in December 2025, where the Phase 2 ACCESS program showed weight loss of up to 15.3% at 36 weeks [2]. The updated results from the ACCESS II trial suggest a continuing trend of efficacy over a longer duration of treatment.
The Boston-based company released these findings alongside its quarterly financial performance to provide investors with a clearer picture of its clinical pipeline [1]. The company is focusing on the commercialization prospects of aleniglipron as it moves through the regulatory pipeline [1], [2].
Structure Therapeutics is positioning the drug to compete in a high-growth sector of the pharmaceutical industry. By focusing on an oral delivery method, the company aims to differentiate its product from the primary injectable options currently available to patients [1].
“aleniglipron demonstrated a maximum body-weight loss of 16.3%”
The shift from 15.3% weight loss at 36 weeks to 16.3% at 44 weeks indicates that aleniglipron may maintain its efficacy over longer periods. If the drug continues to show strong results in Phase 2 trials, it could challenge the current market dominance of injectable GLP-1s by offering a more convenient oral administration route, potentially lowering the barrier for millions of patients seeking obesity treatment.
